Adult Idiopathic Inflammatory Myopathy With Cardiac Injury
A Prospective Cohort Study to Identify a Stratified Approach in the Diagnosis, Treatment in Adult Idiopathic Inflammatory Myopathy With Cardiac Injury
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Qiang Wang, MD PHD
- Phone Number: 862568307588
- Email: jerrytortoise@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients who had a confirmed (muscular biopsy, electromyogram, magnetic resonance imaging) or suspected clinically myositis
- Age over 18 years old
- Signature of the informed consent form for the study
Exclusion Criteria:
- Patients with disease duration >2 years
- Patients < 18 years
- Confirmed non-inflammatory myopathies
- Myositis secondary to alcohol or drug abuse
- Patients unwilling or unable to give consent
- Patients with poor or no venous access
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
idiopathic inflammatory myopathy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The emergence of late gadolinium enhancement (LGE) positive in the different myositis subgroups based on radiological evaluations
Time Frame: 20 years
|
On the basis of the late gadolinium enhancement (LGE) positive by CMR
|
20 years
|
|
The emergence of extra-cellular volume (ECV) > 30% in the different myositis subgroups based on radiological evaluations
Time Frame: 20 years
|
On the basis of extra-cellular volume (ECV) > 30% by CMR
|
20 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with a significant change levels of diagnostic biomarkers
Time Frame: 20 years
|
This will depend on the specific biomarker/cytokine being measured
|
20 years
|
|
Differences in frequency of genetic variants associated with IIM and subtypes compared to population matched controls
Time Frame: 20 years
|
Specific identified genetic variants will be identified as part of large scale genetic studies
|
20 years
|
|
Incidence of major cardio-vascular events
Time Frame: 20 years
|
20 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IIMCI-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.